Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
26
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Torres Raul Cardona | SVP, Quality | 6 | $0 | $0 | 2017-08-29 |
| Eykerman Philip | Director | 2 | $700.0K | $0 | 2017-08-29 |
| Tanda Stephan B. | Director | 2 | $0 | $0 | 2017-08-29 |
| Negron Francisco R. | President, Drug Product Svcs | 7 | $0 | $0 | 2017-08-29 |
| Utiger Lukas | President, Drug Substance Svcs | 7 | $0 | $0 | 2017-08-29 |
| Sherbet Eric | General Counsel and Secretary | 7 | $0 | $0 | 2017-08-29 |
| Pisano Gary P. | Director | 5 | $0 | $0 | 2017-08-29 |
| Cogut Charles I | Director | 2 | $0 | $0 | 2017-08-29 |
| Gill Harry R III | SVP, Quality/Continuous Imprvt | 7 | $0 | $0 | 2017-08-29 |
| New Rebecca Holland | EVP, Enterprise Operations | 7 | $0 | $0 | 2017-08-29 |
| Lagarde Michel | President | 6 | $0 | $0 | 2017-08-29 |
| JLL Associates V (Patheon), L.P. | 10% Owner | 6 | $0 | $0 | 2017-08-29 |
| Wilson Dean Frederick | Chief Accounting Officer | 3 | $0 | $0 | 2017-08-29 |
| Lehmann Michael J. | EVP, Sales & Marketing | 7 | $0 | $0 | 2017-08-29 |
| Grant Stuart | EVP and CFO | 3 | $0 | $0 | 2017-08-29 |
| Hayes William B | Director | 5 | $0 | $0 | 2017-08-29 |
| McMullen Jeffrey P | Director | 6 | $198.5K | $0 | 2017-08-29 |
| Daley Pamela | Director | 7 | $968.7K | $0 | 2017-08-29 |
| SCHNEIER CRAIG ERIC | Executive Vice President & CTO | 3 | $0 | $0 | 2017-08-29 |
| MULLEN JAMES C | Chief Executive Officer | 7 | $0 | $0 | 2017-08-29 |
| HASLER HANS PETER | Director | 6 | $0 | $0 | 2017-08-29 |
| COTTIER GILLES | President, Pharma Dev Svcs | 4 | $0 | $0 | 2017-08-29 |
| Koninklijke DSM N.V. | 10% Owner | 2 | $0 | $94.52M | 2017-08-29 |
| LEVY PAUL S | Director | 7 | $1.78M | $0 | 2017-08-29 |
| JLL Partners Fund VI (Patheon), L.P. | 10% Owner | 2 | $16.19M | $0 | 2016-07-26 |
| LYTTON MICHAEL | EVP, Corp Development & Strtgy | 1 | $0 | $0 | 2016-07-20 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| COTTIER GILLES | President, Pharma Dev Svcs | D To issuer deriv | 2017-08-29 | 2017-08-31 | 123,754 | — | $0 | 0 | SEC↗ |
| Gill Harry R III | SVP, Quality/Continuous Impr | D To issuer deriv | 2017-08-29 | 2017-08-31 | 18,400 | — | $0 | 0 | SEC↗ |
| Lehmann Michael J. | EVP, Global Sales and Mktng | D To issuer deriv | 2017-08-29 | 2017-08-31 | 28,508 | — | $0 | 0 | SEC↗ |
| MULLEN JAMES C | Chief Executive Officer | D To issuer deriv | 2017-08-29 | 2017-08-31 | 242,885 | — | $0 | 0 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | D To issuer deriv | 2017-08-29 | 2017-08-31 | 29,195 | — | $0 | 0 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | D To issuer deriv | 2017-08-29 | 2017-08-31 | 26,791 | — | $0 | 0 | SEC↗ |
| SCHNEIER CRAIG ERIC | EVP and Chief Talent Officer | D To issuer deriv | 2017-08-29 | 2017-08-31 | 96,455 | — | $0 | 0 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | D To issuer deriv | 2017-08-29 | 2017-08-31 | 32,630 | — | $0 | 0 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | D To issuer deriv | 2017-08-29 | 2017-08-31 | 17,174 | — | $0 | 0 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | D To issuer deriv | 2017-08-29 | 2017-08-31 | 21,786 | — | $0 | 0 | SEC↗ |
| Utiger Lukas | President, Drug Substance Sv | D To issuer deriv | 2017-08-29 | 2017-08-31 | 32,287 | — | $0 | 0 | SEC↗ |
| Lagarde Michel | President | D To issuer deriv | 2017-08-29 | 2017-08-31 | 110,402 | — | $0 | 0 | SEC↗ |
| Koninklijke DSM N.V. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 48,697,292 | $35.00 | $1.70B | 0 | SEC↗ |
| Cogut Charles I | Director | U Tender | 2017-08-29 | 2017-08-30 | 4,061 | $35.00 | $142.1K | 0 | SEC↗ |
| Daley Pamela | Director | U Tender | 2017-08-29 | 2017-08-30 | 67,120 | $35.00 | $2.35M | 0 | SEC↗ |
| Eykerman Philip | Director | U Tender | 2017-08-29 | 2017-08-30 | 28,000 | $35.00 | $980.0K | 0 | SEC↗ |
| HASLER HANS PETER | Director | U Tender | 2017-08-29 | 2017-08-30 | 16,864 | $35.00 | $590.2K | 0 | SEC↗ |
| Hayes William B | Director | U Tender | 2017-08-29 | 2017-08-30 | 17,447 | $35.00 | $610.6K | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 24,455,392 | $35.00 | $855.94M | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 4,996,397 | $35.00 | $174.87M | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 5,975,840 | $35.00 | $209.15M | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 40,287 | $35.00 | $1.41M | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 19,985,589 | $35.00 | $699.50M | 0 | SEC↗ |
| JLL Associates V (Patheon), L. | 10% Owner | U Tender | 2017-08-29 | 2017-08-30 | 7,013,339 | $35.00 | $245.47M | 0 | SEC↗ |
| LEVY PAUL S | Director | U Tender | 2017-08-29 | 2017-08-30 | 62,000 | $35.00 | $2.17M | 0 | SEC↗ |
| McMullen Jeffrey P | Director | U Tender | 2017-08-29 | 2017-08-30 | 27,447 | $35.00 | $960.6K | 0 | SEC↗ |
| Pisano Gary P. | Director | U Tender | 2017-08-29 | 2017-08-30 | 17,447 | $35.00 | $610.6K | 0 | SEC↗ |
| Tanda Stephan B. | Director | U Tender | 2017-08-29 | 2017-08-30 | 4,659 | $35.00 | $163.1K | 0 | SEC↗ |
| COTTIER GILLES | President, Pharma Dev Svcs | U Tender | 2017-08-29 | 2017-08-31 | 70,141 | — | $0 | 0 | SEC↗ |
| Gill Harry R III | SVP, Quality/Continuous Impr | U Tender | 2017-08-29 | 2017-08-31 | 305,094 | $35.00 | $10.68M | 0 | SEC↗ |
| Gill Harry R III | SVP, Quality/Continuous Impr | J Other | 2017-08-29 | 2017-08-31 | 105,800 | — | $0 | 0 | SEC↗ |
| Gill Harry R III | SVP, Quality/Continuous Impr | U Tender | 2017-08-29 | 2017-08-31 | 7,078 | — | $0 | 105,800 | SEC↗ |
| Grant Stuart | EVP and CFO | U Tender | 2017-08-29 | 2017-08-31 | 566,603 | $35.00 | $19.83M | 0 | SEC↗ |
| Grant Stuart | EVP and CFO | J Other | 2017-08-29 | 2017-08-31 | 196,485 | — | $0 | 0 | SEC↗ |
| Lehmann Michael J. | EVP, Global Sales and Mktng | U Tender | 2017-08-29 | 2017-08-31 | 373,754 | $35.00 | $13.08M | 0 | SEC↗ |
| Lehmann Michael J. | EVP, Global Sales and Mktng | J Other | 2017-08-29 | 2017-08-31 | 191,772 | — | $0 | 0 | SEC↗ |
| Lehmann Michael J. | EVP, Global Sales and Mktng | U Tender | 2017-08-29 | 2017-08-31 | 10,966 | — | $0 | 191,772 | SEC↗ |
| MULLEN JAMES C | Chief Executive Officer | U Tender | 2017-08-29 | 2017-08-31 | 93,432 | — | $0 | 906,858 | SEC↗ |
| MULLEN JAMES C | Chief Executive Officer | U Tender | 2017-08-29 | 2017-08-31 | 2,615,089 | $35.00 | $91.53M | 0 | SEC↗ |
| MULLEN JAMES C | Chief Executive Officer | J Other | 2017-08-29 | 2017-08-31 | 906,858 | — | $0 | 0 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | U Tender | 2017-08-29 | 2017-08-31 | 11,231 | — | $0 | 261,322 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | J Other | 2017-08-29 | 2017-08-31 | 261,322 | — | $0 | 0 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | U Tender | 2017-08-29 | 2017-08-31 | 330,169 | $35.00 | $11.56M | 0 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | U Tender | 2017-08-29 | 2017-08-31 | 10,306 | — | $0 | 161,543 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | U Tender | 2017-08-29 | 2017-08-31 | 286,585 | $35.00 | $10.03M | 0 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | J Other | 2017-08-29 | 2017-08-31 | 161,543 | — | $0 | 0 | SEC↗ |
| SCHNEIER CRAIG ERIC | EVP and Chief Talent Officer | U Tender | 2017-08-29 | 2017-08-31 | 48,755 | $35.00 | $1.71M | 0 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | U Tender | 2017-08-29 | 2017-08-31 | 129,595 | $35.00 | $4.54M | 0 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | J Other | 2017-08-29 | 2017-08-31 | 219,330 | — | $0 | 0 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | U Tender | 2017-08-29 | 2017-08-31 | 12,552 | — | $0 | 219,330 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | U Tender | 2017-08-29 | 2017-08-31 | 13,112 | — | $0 | 0 | SEC↗ |
| Utiger Lukas | President, Drug Substance Sv | J Other | 2017-08-29 | 2017-08-31 | 191,772 | — | $0 | 0 | SEC↗ |
| Utiger Lukas | President, Drug Substance Sv | U Tender | 2017-08-29 | 2017-08-31 | 12,420 | — | $0 | 191,772 | SEC↗ |
| Utiger Lukas | President, Drug Substance Sv | U Tender | 2017-08-29 | 2017-08-31 | 373,754 | $35.00 | $13.08M | 0 | SEC↗ |
| Wilson Dean Frederick | Chief Accounting Officer | U Tender | 2017-08-29 | 2017-08-31 | 126,518 | — | $0 | 0 | SEC↗ |
| Lagarde Michel | President | U Tender | 2017-08-29 | 2017-08-31 | 245,939 | — | $0 | 0 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | F Tax w/h | 2017-07-20 | 2017-07-24 | 786 | $34.90 | $27.4K | 13,112 | SEC↗ |
| SCHNEIER CRAIG ERIC | Executive Vice President & C | F Tax w/h | 2017-07-20 | 2017-07-24 | 5,914 | $34.90 | $206.4K | 48,755 | SEC↗ |
| Lagarde Michel | President | F Tax w/h | 2017-07-20 | 2017-07-24 | 34,625 | $34.90 | $1.21M | 245,939 | SEC↗ |
| Lehmann Michael J. | EVP, Sales & Marketing | A Award deriv | 2017-03-23 | 2017-03-27 | 28,508 | — | $0 | 28,508 | SEC↗ |
| Utiger Lukas | President, Drug Substance | A Award deriv | 2017-03-23 | 2017-03-27 | 32,287 | — | $0 | 32,287 | SEC↗ |
| Gill Harry R III | SVP, Quality & Improvement | A Award deriv | 2017-03-23 | 2017-03-27 | 18,400 | — | $0 | 18,400 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | A Award deriv | 2017-03-23 | 2017-03-27 | 32,630 | — | $0 | 32,630 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | A Award deriv | 2017-03-23 | 2017-03-27 | 26,791 | — | $0 | 26,791 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | A Award deriv | 2017-03-23 | 2017-03-27 | 29,195 | — | $0 | 29,195 | SEC↗ |
| Lagarde Michel | President | A Award deriv | 2017-03-23 | 2017-03-27 | 110,402 | — | $0 | 110,402 | SEC↗ |
| MULLEN JAMES C | CEO | A Award deriv | 2017-03-23 | 2017-03-27 | 242,885 | — | $0 | 242,885 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | A Award deriv | 2017-03-23 | 2017-03-27 | 17,174 | — | $0 | 17,174 | SEC↗ |
| Cogut Charles I | Director | A Award | 2017-03-23 | 2017-03-27 | 4,061 | — | $0 | 4,061 | SEC↗ |
| Daley Pamela | Director | A Award | 2017-03-23 | 2017-03-27 | 873 | — | $0 | 18,320 | SEC↗ |
| Daley Pamela | Director | A Award | 2017-03-23 | 2017-03-27 | 6,229 | — | $0 | 17,447 | SEC↗ |
| Tanda Stephan B. | Director | A Award | 2017-03-23 | 2017-03-27 | 4,659 | — | $0 | 4,659 | SEC↗ |
| Hayes William B | Director | A Award | 2017-03-23 | 2017-03-27 | 6,229 | — | $0 | 17,447 | SEC↗ |
| HASLER HANS PETER | Director | A Award | 2017-03-23 | 2017-03-27 | 897 | — | $0 | 16,864 | SEC↗ |
| HASLER HANS PETER | Director | A Award | 2017-03-23 | 2017-03-27 | 6,229 | — | $0 | 15,967 | SEC↗ |
| McMullen Jeffrey P | Director | A Award | 2017-03-23 | 2017-03-27 | 6,229 | — | $0 | 17,447 | SEC↗ |
| Pisano Gary P. | Director | A Award | 2017-03-23 | 2017-03-27 | 6,229 | — | $0 | 17,447 | SEC↗ |
| Wilson Dean Frederick | Chief Accounting Officer | A Award | 2017-03-23 | 2017-03-27 | 8,519 | — | $0 | 126,518 | SEC↗ |
| Lehmann Michael J. | EVP, Sales & Marketing | A Award | 2017-03-23 | 2017-03-27 | 10,966 | — | $0 | 202,738 | SEC↗ |
| Utiger Lukas | President, Drug Substance | A Award | 2017-03-23 | 2017-03-27 | 12,420 | — | $0 | 204,192 | SEC↗ |
| Gill Harry R III | SVP, Quality & Improvement | A Award | 2017-03-23 | 2017-03-27 | 7,078 | — | $0 | 112,878 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | A Award | 2017-03-23 | 2017-03-27 | 12,552 | — | $0 | 231,882 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | A Award | 2017-03-23 | 2017-03-27 | 10,306 | — | $0 | 171,849 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | A Award | 2017-03-23 | 2017-03-27 | 11,231 | — | $0 | 272,553 | SEC↗ |
| Lagarde Michel | President | A Award | 2017-03-23 | 2017-03-27 | 42,469 | — | $0 | 280,564 | SEC↗ |
| MULLEN JAMES C | CEO | A Award | 2017-03-23 | 2017-03-27 | 93,432 | — | $0 | 1,000,290 | SEC↗ |
| Torres Raul Cardona | SVP, Quality | A Award | 2017-03-23 | 2017-03-27 | 6,606 | — | $0 | 13,898 | SEC↗ |
| Daley Pamela | Director | F Tax w/h | 2016-11-01 | 2016-11-02 | 687 | $25.61 | $17.6K | 11,218 | SEC↗ |
| Daley Pamela | Director | M Exercise | 2016-11-01 | 2016-11-02 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Hayes William B | Director | M Exercise | 2016-11-01 | 2016-11-02 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Hayes William B | Director | F Tax w/h | 2016-11-01 | 2016-11-02 | 687 | $25.61 | $17.6K | 11,218 | SEC↗ |
| HASLER HANS PETER | Director | F Tax w/h | 2016-11-01 | 2016-11-02 | 2,167 | $25.61 | $55.5K | 9,738 | SEC↗ |
| HASLER HANS PETER | Director | M Exercise | 2016-11-01 | 2016-11-02 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Pisano Gary P. | Director | F Tax w/h | 2016-11-01 | 2016-11-02 | 687 | $25.61 | $17.6K | 11,218 | SEC↗ |
| Pisano Gary P. | Director | M Exercise | 2016-11-01 | 2016-11-02 | 11,905 | — | $0 | 11,905 | SEC↗ |
| McMullen Jeffrey P | Director | M Exercise | 2016-11-01 | 2016-11-02 | 11,905 | — | $0 | 11,905 | SEC↗ |
| McMullen Jeffrey P | Director | F Tax w/h | 2016-11-01 | 2016-11-02 | 687 | $25.61 | $17.6K | 11,218 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-30 | 2016-10-03 | 5,000 | $29.80 | $149.0K | 62,000 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-29 | 2016-10-03 | 5,000 | $29.30 | $146.5K | 57,000 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-28 | 2016-09-28 | 5,000 | $29.61 | $148.1K | 52,000 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-27 | 2016-09-28 | 5,000 | $29.65 | $148.3K | 47,000 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-26 | 2016-09-28 | 5,000 | $29.65 | $148.3K | 42,000 | SEC↗ |
| LEVY PAUL S | Director | P Buy | 2016-09-12 | 2016-09-14 | 37,000 | $28.01 | $1.04M | 37,000 | SEC↗ |
| Koninklijke DSM N.V. | 10% Owner | S Sale | 2016-07-26 | 2016-07-28 | 4,761,905 | $19.85 | $94.52M | 48,697,292 | SEC↗ |
| Daley Pamela | Director | P Buy | 2016-07-26 | 2016-07-28 | 48,800 | $19.85 | $968.7K | 60,705 | SEC↗ |
| McMullen Jeffrey P | Director | P Buy | 2016-07-26 | 2016-07-28 | 10,000 | $19.85 | $198.5K | 21,905 | SEC↗ |
| JLL Partners Fund VI (Patheon) | 10% Owner | P Buy | 2016-07-26 | 2016-07-28 | 40,287 | $19.85 | $799.7K | 40,287 | SEC↗ |
| JLL Partners Fund VI (Patheon) | 10% Owner | P Buy | 2016-07-26 | 2016-07-28 | 775,443 | $19.85 | $15.39M | 24,455,392 | SEC↗ |
| Eykerman Philip | Director | P Buy | 2016-07-21 | 2016-07-25 | 28,000 | $25.00 | $700.0K | 28,000 | SEC↗ |
| COTTIER GILLES | President, Pharma Dev Svcs | A Award deriv | 2016-07-20 | 2016-07-22 | 123,754 | — | $0 | 123,754 | SEC↗ |
| COTTIER GILLES | President, Pharma Dev Svcs | A Award | 2016-07-20 | 2016-07-22 | 70,141 | — | $0 | 70,141 | SEC↗ |
| Daley Pamela | Director | A Award | 2016-07-20 | 2016-07-22 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Gill Harry R III | SVP, Quality/Continuous Impr | A Award | 2016-07-20 | 2016-07-22 | 105,800 | — | $0 | 105,800 | SEC↗ |
| Grant Stuart | EVP and CFO | A Award | 2016-07-20 | 2016-07-22 | 196,485 | — | $0 | 196,485 | SEC↗ |
| HASLER HANS PETER | Director | A Award | 2016-07-20 | 2016-07-22 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Hayes William B | Director | A Award | 2016-07-20 | 2016-07-22 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Lagarde Michel | President | A Award | 2016-07-20 | 2016-07-22 | 238,095 | — | $0 | 238,095 | SEC↗ |
| Lehmann Michael J. | EVP, Global Sales and Mktng | A Award | 2016-07-20 | 2016-07-22 | 191,772 | — | $0 | 191,772 | SEC↗ |
| LYTTON MICHAEL | EVP, Corp Development & Strt | A Award | 2016-07-20 | 2016-07-22 | 227,201 | — | $0 | 227,201 | SEC↗ |
| McMullen Jeffrey P | Director | A Award | 2016-07-20 | 2016-07-22 | 11,905 | — | $0 | 11,905 | SEC↗ |
| MULLEN JAMES C | Chief Executive Officer | A Award | 2016-07-20 | 2016-07-22 | 906,858 | — | $0 | 906,858 | SEC↗ |
| Negron Francisco R. | President, Drug Product Svcs | A Award | 2016-07-20 | 2016-07-22 | 261,322 | — | $0 | 261,322 | SEC↗ |
| New Rebecca Holland | EVP, Enterprise Operations | A Award | 2016-07-20 | 2016-07-22 | 161,543 | — | $0 | 161,543 | SEC↗ |
| Pisano Gary P. | Director | A Award | 2016-07-20 | 2016-07-22 | 11,905 | — | $0 | 11,905 | SEC↗ |
| Sherbet Eric | General Counsel and Secretar | A Award | 2016-07-20 | 2016-07-22 | 219,330 | — | $0 | 219,330 | SEC↗ |
| Utiger Lukas | President, Drug Substance Sv | A Award | 2016-07-20 | 2016-07-22 | 191,772 | — | $0 | 191,772 | SEC↗ |
| Wilson Dean Frederick | Chief Accounting Officer | A Award | 2016-07-20 | 2016-07-22 | 117,999 | — | $0 | 117,999 | SEC↗ |